Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study von Calabresi, Peter A, Prof, Kieseier, Bernd C, MD, Arnold, Douglas L, Prof, Balcer, Laura J, Prof, Boyko, Alexey, Prof, Pelletier, Jean, MD, Liu, Shifang, PhD, Zhu, Ying, PhD, Seddighzadeh, Ali, MD, Hung, Serena, MD, Deykin, Aaron, MD

Volltext

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial von White, Joleen T., Newsome, Scott D., Kieseier, Bernd C., Bermel, Robert A., Cui, Yue, Seddighzadeh, Ali, Hung, Serena, Crossman, Mary, Subramanyam, Meena

Volltext

Venous thromboembolism in patients with active cancer von Seddighzadeh, Ali, Shetty, Ranjith, Goldhaber, Samuel Z.

Volltext

Heart Failure in Patients With Deep Vein Thrombosis von Piazza, Gregory, MD, Seddighzadeh, Ali, MD, MSc, Goldhaber, Samuel Z., MD

Volltext

Deep vein thrombosis in patients with chronic kidney disease von Daneschvar, H. Leon, Seddighzadeh, Ali, Piazza, Gregory, Goldhaber, Samuel Z.

Volltext

Deep-Vein Thrombosis in the Elderly von Piazza, Gregory, Seddighzadeh, Ali, Goldhaber, Samuel Z.

Volltext

Venous thromboembolism in patients undergoing surgery: Low rates of prophylaxis and high rates of filter insertion von Seddighzadeh, Ali, Zurawska, Urszula, Shetty, Ranjith, Goldhaber, Samuel Z.

Volltext

Deep Vein Thrombosis in Orthopedic Surgery von Calfon, Marcella, Seddighzadeh, Ali, Piazza, Gregory, Goldhaber, Samuel Z.

Volltext

Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database von Snopek, Frank, Seddighzadeh, Ali, Flynn, Megan, Cai, Ling-Yu, Chen, Esther, Shih, Weichung Joe, Qin, Albert, Urbanski, Raymond W

Volltext

Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis von Piazza, Gregory, Seddighzadeh, Ali, Goldhaber, Samuel Z.

Volltext

Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism von Shetty, Ranjith, Seddighzadeh, Ali, Parasuraman, Sudha, Vallurupalli, Neelima G., Herman, Marie Gerhard, Goldhaber, Samuel Z.

Volltext

Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis : Prophylaxis omitted more often and pulmonary embolism more frequent von PIAZZA, Gregory, SEDDIGHZADEH, Ali, GOLDHABER, Samuel Z

Volltext

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children von Sas, David J., Magen, Daniella, Hayes, Wesley, Shasha-Lavsky, Hadas, Michael, Mini, Schulte, Indra, Sellier-Leclerc, Anne-Laure, Lu, Jiandong, Seddighzadeh, Ali, Habtemariam, Bahru, McGregor, Tracy L., Fujita, Kenji P., Frishberg, Yaacov, Bacchetta, Justine, Baudouin, Véronique, Becker-Cohen, Rachel, Tzvi Behr, Shimrit, Ben-Shalom, Efrat, Berdaguer, Maria, Bockenhauer, Detlef, Cochat, Pierre, Coenen, Martin, Cramer, Carl H., Deschênes, Georges, Dossier, Claire, Doye, Emilie, Feldman, Liat Feraru, Hohenadel, Maximilian, Kaguelidou, Florentia, Zebegret, Irina Libinson, Lieske, John C., Maisin, Anne, Milliner, Dawn S., Plonsky Toder, Moran, Pollack, Shirley, Portefaix, Aurélie, Ranchin, Bruno, Rinat, Choni, Safdar, Adnan, Schalk, Gesa, Srivaths, Poyyapakkam R., Tran, Cheryl L., Van't Hoff, William, Weinbrand-Goichberg, Jenny, Weissman, Irith

Volltext

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE von Kieseier, Bernd C, Arnold, Douglas L, Balcer, Laura J, Boyko, Alexey A, Pelletier, Jean, Liu, Shifang, Zhu, Ying, Seddighzadeh, Ali, Hung, Serena, Deykin, Aaron, Sheikh, Sarah I, Calabresi, Peter A

Volltext

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects von Hu, Xiao, Shang, Shulian, Nestorov, Ivan, Hasan, Jawad, Seddighzadeh, Ali, Dawson, Katherine, Sperling, Bjørn, Werneburg, Brian

Volltext

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis von Hu, Xiao, Hang, Yaming, Cui, Yue, Zhang, Jie, Liu, Shifang, Seddighzadeh, Ali, Deykin, Aaron, Nestorov, Ivan

Volltext

ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1): PO1624 von Michael, Mini, Deschênes, Georges, Cochat, Pierre, Magen, Daniella, van’t Hoff, William, Sas, David J., Schalk, Gesa, Shasha-Lavsky, Hadas, Hayes, Wesley N., Bae, Kyounghwa, Seddighzadeh, Ali, Garg, Pushkal, Vaishnaw, Akshay, McGregor, Tracy, Fujita, Kenji, Frishberg, Yaacov

Volltext

Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy von Seddighzadeh, Ali, Wolf, Anne T., Parasuraman, Sudha, Shetty, Ranjith, Vallurupalli, Neelima, Reddy, Sarathchandra, Goldhaber, Samuel Z.

Volltext

Long-Term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis From ATTAIN, a Phase 3 Extension Study (S4.002) von Kremenchutzky, Marcelo, Liu, Shifang, Cui, Yue, Hung, Serena, Seddighzadeh, Ali, Evilevitch, Vladimir

Volltext

Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function von Hu, Xiao, Seddighzadeh, Ali, Stecher, Scott, Zhu, Ying, Goyal, Jaya, Matson, Mark, Marbury, Thomas, Smith, William, Nestorov, Ivan, Hung, Serena

Volltext